PHILADELPHIA, July 24, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced a series of industry-first milestones in its Cortellis platform. Cortellis, the premier source of life sciences competitive intelligence information and analytics, has reached new content milestones with more than 50,000 investigational drugs, 400,000 bioactive compounds, and six million biologically active patents. In total, the solution contains over 15 million expert, human-curated reports featuring deal information, patents, literature and clinical trials data.
The Cortellis milestones are in addition to new data being integrated into the platform as a result of three recent acquisitions. These include Deloitte Recap, the leading biopharmaceutical provider of life science deals, acquisitions data and analytics; BioWorld and Medical Device Daily, premiere daily news sources in the biopharma and medical device industries; and Timely Data Resources, the esteemed provider of epidemiology information for biopharmaceutical companies, device manufacturers, universities and research institutions. This collective content confirms Cortellis as the industry leading solution for drug discovery, development and commercialization.
"Given the overwhelming amount of public data available, life science professionals need a way to access accurate and relevant information and analytics to support strategic decisions throughout the drug development process," said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. "Their need underscores the reasoning behind our editorial process and unique Cortellis technology: make the best content findable and actionable for our pharmaceutical customers. Our recent milestones in content breadth, as well as our recent acquisitions, add to the decision-making power we give these professionals."
Thomson Reuters employs a rigorous review process for each investigational drug featured in Cortellis. The editorial team combs through two-to-three year's worth of information, compiling a unique profile that includes basic drug information as well as recent news articles, publications, events, and more. Users benefit from an all-in-one-place summary of the compound, without having to spend days researching and parsing information on their own.
Reports on trials, literature, patents and deals are also manually curated and revised daily by industry experts to ensure they contain the most up-to-date competitive intelligence from over 40,000 sources. In addition to providing sophisticated analytics and visualizations within Cortellis, the platform also has an open architecture that allows information to be easily incorporated into other software solutions and customer workflows to enable faster decision making.
Follow Cortellis (@Cortellis) on Twitter for the latest news in drug discovery, development, regulatory, commercialization, forecast and generics intelligence.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.
|SOURCE Thomson Reuters|
Copyright©2012 PR Newswire.
All rights reserved